Clinical trial

GVAX in Advanced Prostate Cancer Patients Made Lymphopenic

NCT00122005

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2005-07-01

PhasePHASE1 / PHASE2

Study timeline

Study start (unknown)2005-07-01Date precision: month

Registry last updated2009-02-24

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Interventions

GM-CSF gene transduced allogeneic vaccine GVAXBIOLOGICAL

Sponsors & collaborators

Providence Health & Serviceslead sponsor

Providence Cancer Center, Earle A. Chiles Research Institutecollaborator

Cell Genesyscollaborator

Mapped research locations

PortlandOregon, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00122005 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.